In The Field
Neuroscience 2008: New ‘epigenetic’ memory drug
Michael Ahlijanian, a vice-president of the small biotech company EnVivo, told the meeting that the company’s new compound EVP-0334 is to enter clinical trials for treating memory disorders ‘very soon’. That it has made it so far is surprising and scientifically interesting, particularly since it acts by interfering with epigenetic phenomena in the brain.